Dengvaxia,
world's first vaccine for the deadly disease dengue has been approved in 11
more countries.
Dengvaxia was approved by the Health Sciences Authority on Tuesday
following a seven-month review into its potential benefits and risks, and will
be made commercially available in several months' time.
Sanofi-Pasteur,
a unit of French pharmaceutical company Sanofi, that manufactures the only
approved dengue vaccine on Tuesday said that the vaccines has received approval
in 14 countries.
Recently, the health
authorities of Indonesia, Thailand and Singapore have granted the approvals for
Dengvaxia. Mexico, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay,
Guatemala, Peru, Indonesia, Thailand and Singapore have already granted it the
approval.
The dengue vaccine also
prevented eight of 10 hospitalisations due to dengue and 93 per cent of serious
dengue cases like the deadly hemorrhagic form of the disease, over the 25-month
study follow-up period of the large-scale efficacy studies conducted in 10
endemic countries in Latin America and Asia.
Dengue: which causes flu-like illness, and occasionally
develops into a potentially lethal complication called severe dengue -- has
long been an issue on the small tropical island nation.
According to information from the
National Environment Agency, there are currently six high risk areas in the
country where 10 or more cases of dengue have been logged.
According to major clinical studies
involving individuals between the ages of two and 16, Dengvaxia is effective in
reducing dengue illness by 60 per cent, and severe dengue illness by 84 per
cent.
For more details check below links:
No comments:
Post a Comment